Skip to main content

Advertisement

SpringerLink
Log in

Lymphadenectomy in Ovarian Cancer: Is It Still Justified?

  • Gynecologic Cancers (NS Reed, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The aim of this review is to determine, in the light of recent evidences, the role of lymphadenectomy in ovarian cancer.

Recent Findings

The lymphadenectomy in ovarian neoplasms (LION) trial reports no better outcomes and higher complication and mortality rates associated with lymphadenectomy. Even if performed by expert hands, lymphadenectomy has a cost in terms of longer operative time, blood loss, higher rates of transfusions, and intensive unit care.

Summary

If on the one hand retroperitoneal staging is not correlated to survival benefits both in early and advanced ovarian cancer, on the other hand it is associated with an increased surgery-related morbidity. Surgical treatment of isolated nodal recurrences seems to be feasible and associated with survival benefits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, GLOBOCAN 2008 (Version 1.2), Cancer incidence and mortality worldwide, Lyon, France, International Agency for Research on Cancer, 2010 Available from

  2. Musella A, Vertechy L, Romito A, Marchetti C, Giannini A, Sciuga V, et al. Bevacizumab in ovarian cancer: state of the art and unanswered questions. Chemotherapy. 2017;62(2):111–20. https://doi.org/10.1159/000448942 Epub 2016 Oct 29. Review.PMID: 27794568.

    Article  CAS  PubMed  Google Scholar 

  3. Cancer Statistics Center, American Cancer Society, cancerstatisticscenter.otg.

  4. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.

    Article  PubMed  Google Scholar 

  5. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER cancer statistics review, 1975–2001. Bethesda (MD): National Cancer Institute.

  6. American Cancer Society: ovarian cancer, Available at: www.cancer.org Last accessed: December 11, 2016.

  7. Desteli D, Gultekin M, Usubutin A, et al. Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: hacettepe experience and review of literature. World J Surg Oncol. 2010;30(8):106.

    Article  Google Scholar 

  8. Benedetti-Panici P, Greggi S, Maneschi F, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol. 1993;51:150–4.

    Article  CAS  PubMed  Google Scholar 

  9. Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197:198–205.

    Article  PubMed  Google Scholar 

  10. Pereira A, Pérez-Medina T, Magrina JF, et al. Correlation between the extent of intraperitoneal disease and nodal metastasis in node-positive ovarian cancer patients. Eur J Surg Oncol. 2014;40(8):917–24.

    Article  CAS  PubMed  Google Scholar 

  11. Legge F, Petrillo M, Adamo V, et al. Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer. 2008;8:367.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Signorelli M, Guerra L, Pirovano C, et al. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol. 2013;131(2):395–9.

    Article  PubMed  Google Scholar 

  13. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35(10):1912–20. https://doi.org/10.1007/s00259-008-0890-2.

    Article  PubMed  Google Scholar 

  14. De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, et al. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol. 2011;80(2):e98–103. https://doi.org/10.1016/j.ejrad.2010.07.013 Epub 2010 Aug 4.

    Article  PubMed  Google Scholar 

  15. Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123(3):610–4. https://doi.org/10.1016/j.ygyno.2011.09.013 Epub 2011 Oct 6. Review.

    Article  CAS  PubMed  Google Scholar 

  16. Bogani G, Tagliabue E, Ditto A, Signorelli M, Martinelli F, Casarin J, et al. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: a predictors- and nomogram-based analyses. Gynecol Oncol. 2017;147(1):61–5. https://doi.org/10.1016/j.ygyno.2017.07.139 Epub 2017 Aug 2.

    Article  PubMed  Google Scholar 

  17. Lago V, Minig L, Fotopoulou C. Incidence of lymph node metastases in apparent early-stage low-grade epithelial ovarian cancer: a comprehensive review. Int J Gynecol Cancer. 2016;26(8):1407–14. https://doi.org/10.1097/IGC.0000000000000787 Review.

    Article  PubMed  Google Scholar 

  18. Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122(3):536–40. https://doi.org/10.1016/j.ygyno.2011.05.001 Epub 2011 Jun 1.

    Article  PubMed  Google Scholar 

  19. • Maggioni A, Benedetti Panici P, Dell-Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95(6):699–704 (A multicentric randomized trial evaluating the value of systematic lymphadenectomy in early EOC demonstrates no statistically significant difference in 5-year overall survival among the lymphadenectomy group and the control group.).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, et al. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Am J Clin Oncol. 2008;31(1):39–42. https://doi.org/10.1097/COC.0b013e318134ee6f.

    Article  PubMed  Google Scholar 

  21. Colombo N, Pecorelli S. What have we learned from ICON1 and ACTION? Int J Gynecol Cancer. 2003;13(Suppl 2):140–3.

    Article  PubMed  Google Scholar 

  22. • Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560–6 (One of the most important randomized study shows that retroperitoneal staging is correlated with a higher incidence of surgery-related morbidity, post-operative stay, and costs.).

    Article  PubMed  Google Scholar 

  23. Uccella S, Nero C, Vizza E, Vargiu V, Corrado G, Bizzarri N, et al. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY). Am J Obstet Gynecol. 2019;221(4):324.e1–324.e10. https://doi.org/10.1016/j.ajog.2019.05.005 Epub 2019 May 10.

    Article  Google Scholar 

  24. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):24–32.

    Article  Google Scholar 

  25. NCCN Clinical practice guidelines in oncology (NCCN Guidelines Version 2.2019 Panel Members Ovarian Cancer). http://www.nccn.org/professionals/physician_ gls/f_guidelines.asp.

  26. Zhou J, Zhang W, Zhang QG, He ZY, Sun JY, Chen QH, et al. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: a population-based study. Int J Surg. 2018;52:11–5.

    Article  PubMed  Google Scholar 

  27. Harter P, Gnauert K, Hils R, Lehmann TG, Fisseler-Eckhoff A, Traut A, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238–44.

    Article  CAS  PubMed  Google Scholar 

  28. Eisenkop SM, Spirtos NM. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol. 2001;82:143–9.

    Article  CAS  PubMed  Google Scholar 

  29. Ferrero A, Ditto A, Giorda G, et al. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. Eur J Surg Oncol. 2014;40(7):891–8.

    Article  CAS  PubMed  Google Scholar 

  30. Du Bois A, Reuss A, Harter P, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733–9.

    Article  PubMed  Google Scholar 

  31. •• Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822–32. https://doi.org/10.1056/NEJMoa1808424(The last randomized trial shows that level one evidence has no survival benefit correlated to lymphadenectomy in complete debulky ovarian cancer.).

    Article  PubMed  Google Scholar 

  32. • Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G, et al. Trends in mortality after primary cytoreductive surgery for ovarian cancer: a systematic review and metaregression of randomized clinical trials and observational studies. Ann Surg Oncol. 2017;24(6):1688–97. https://doi.org/10.1245/s10434-016-5680-7(This study analyzes all study present in literature and shows incidence and predictor of peri-operative mortality in the surgery treatment for advanced EOC.).

    Article  PubMed  Google Scholar 

  33. Benedetti Panici P, Di Donato V, Fischetti M, Casorelli A, Perniola G, Musella A, et al. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: analysis and management of complications in upper abdominal surgery. Gynecol Oncol. 2015;137(3):406–11. https://doi.org/10.1016/j.ygyno.2015.03.043 Epub 2015 Mar 28.

    Article  PubMed  Google Scholar 

  34. Gasparri ML, Attar R, Palaia I, Perniola G, Marchetti C, Di Donato V, et al. Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J Cancer Prev. 2015;16(9):3635–8 Review.

    Article  PubMed  Google Scholar 

  35. Benedetti Panici P, Perniola G, Angioli R, Zullo MA, Manci N et al. Basile S Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery. Int J Gynecol Cancer 2007;17(6):1245–1251. Epub 2007 Apr 8.

  36. Fotiou S, Aliki T, Petros Z, et al. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol. 2009;114:178–82.

    Article  PubMed  Google Scholar 

  37. Uzan C, Morice P, Rey A, et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol. 2004;11:658–64.

    Article  PubMed  Google Scholar 

  38. Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007;104:686–90.

    Article  PubMed  Google Scholar 

  39. Du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017;35(15_suppl):5501.

    Article  Google Scholar 

  40. Coleman RL, Enserro D, Spirtos N, Herzog TJ, Sabbatini P, Armstrong DK, et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG Oncology/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36(15_suppl):5501. https://doi.org/10.1200/JCO.2018.36.15_suppl.5501.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Maternal and Child Health and Urological Sciences, Umberto I, “Sapienza” University of Rome, Viale del policlinico 155, 0161, Rome, Italy

    Pierluigi Benedetti Panici, Andrea Giannini, Margherita Fischetti, Francesca Lecce & Violante Di Donato

Authors
  1. Pierluigi Benedetti Panici
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Giannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margherita Fischetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesca Lecce
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Violante Di Donato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierluigi Benedetti Panici.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Gynecologic Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Benedetti Panici, P., Giannini, A., Fischetti, M. et al. Lymphadenectomy in Ovarian Cancer: Is It Still Justified?. Curr Oncol Rep 22, 22 (2020). https://doi.org/10.1007/s11912-020-0883-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-020-0883-2

Keywords

Search

Navigation